Lipopolysaccharide Binding Protein and Development of Infectious Events in Cirrhotic Patients
NCT ID: NCT00760032
Last Updated: 2012-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE4
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active
Ciprofloxacin
Ciprofloxacin
Ciprofloxacin oral, 500 mg capsules, one capsule per day during four weeks.
Placebo
Placebo
Placebo
Placebo capsules, one capsule per day during four weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ciprofloxacin
Ciprofloxacin oral, 500 mg capsules, one capsule per day during four weeks.
Placebo
Placebo capsules, one capsule per day during four weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ascites
* No history of spontaneous bacterial peritonitis and/or \< 1 g of protein in ascites
* No antibiotic use in previous 6 weeks
* Absence of infection (documented by clinical history, blood cytology, urinalysis and urine culture, thorax x-ray and paracentesis)
* Absence of GI bleeding or encephalopathy
* Signature of informed consent
Exclusion Criteria
* Autoimmune hepatitis, sclerosing cholangitis or other autoimmune disease
* \> 13 Child-Pugh points
* Inability to attend to regular visits
* Current alcohol intake
* Terminal disease with \< 24 week expected survival
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Laboratorios Senosiain, S.A. de C.V.
INDUSTRY
Florencia Vargas-Vorackova
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Florencia Vargas-Vorackova
Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Florencia Vargas-Vorackova, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
México, D.f., Mexico
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Sponsor's Web site
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
REF. 1612
Identifier Type: -
Identifier Source: secondary_id
GAS-149-07-09-1
Identifier Type: -
Identifier Source: org_study_id